BeyondSpring Inc. (BYSI) shares are falling more than 53 percent on Wednesday morning trade after FDA issued a complete response letter for a new drug application for Plinabulin in combination with granulocyte colony-stimulating factor and said it cannot be approved in its present form. The NDA has intended for the prevention of chemotherapy-induced neutropenia or low levels of white blood cells.
FDA in its letter said the single registrational trial was not sufficiently robust to demonstrate benefit and require a second well-controlled trial.
Currently, shares are at $6.15, down 51.91 percent from the previous close of $12.77 on a volume of 12,172,934. For the 52-week period, the shares have traded in a range of $5.50-$33.00 on average volume of 1,072,116.
For comments and feedback contact: editorial@rttnews.com
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.